01—Abstract
Summary
Summary of the 8-K filed May 8, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated reported first-quarter 2025 financial results on May 8, 2025.
Total ARIKAYCE revenue was $92.8 milliona, up 22.9% from $75.5 million in the first quarter of 2024, with U.S. revenue of $64.3 million (up 14.1%), Japan revenue of $22.1 million (up 48.3%), and Europe & Rest of World revenue of $6.5 million (up 51.8%). The company reiterated its full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million. Net loss widened to $256.6 million, or $1.42 per share, compared with a net loss of $157.1 million, or $1.06 per share, a year earlier.
Research and development expenses were $152.6 millionb and selling, general and administrative expenses were $147.5 million, both up from the prior-year quarter, reflecting headcount growth and preparation for a potential brensocatib launch. The company's pipeline milestones remain central to the investment case. The FDA accepted the New Drug Application for brensocatib in bronchiectasis with Priority Review and a PDUFA target action date of August 12, 2025.
The Phase 2b study of TPIP in pulmonary arterial hypertension has completed, with topline data expected in June 2025. Enrollment is complete in the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps, with topline results expected by the end of 2025. The company also announced a notice of redemption for all $569.5 millionc of its remaining 0.75% Convertible Senior Notes due 2028, with a redemption date of June 6, 2025.
As of March 31, 2025, Insmed reported cash, cash equivalents, and marketable securities of approximately $1.2 billiond, compared with total liabilities of $1.70 billion and total shareholders' equity of $99.2 million on the balance sheet. The filing states the company plans to continue investing in ARIKAYCE commercialization, brensocatib launch preparation, clinical programs, and TPIP development.
02—Key points
Key Highlights
- Total Q1 2025 revenue of $92.8 million, up 22.9% year over year, with U.S. revenue of $64.3 million (up 14.1%), Japan $22.1 million (up 48.3%), and Europe & Rest of World $6.5 million (up 51.8%)
- Net loss of $256.6 million, or $1.42 per share, versus a net loss of $157.1 million, or $1.06 per share, in Q1 2024
- R&D expenses rose to $152.6 million from $121.1 million, and SG&A expenses rose to $147.5 million from $93.1 million, driven by headcount and launch preparation
- Brensocatib NDA for bronchiectasis accepted with Priority Review; PDUFA target action date of August 12, 2025
- Full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million reiterated, which the filing describes as double-digit growth compared with 2024
- Notice of redemption issued for all $569.5 million of remaining 0.75% Convertible Senior Notes due 2028, with redemption on June 6, 2025
- Cash, cash equivalents, and marketable securities of approximately $1.2 billion as of March 31, 2025; TPIP Phase 2b PAH topline data expected in June 2025
03—Questions
Frequently Asked Questions
Is Insmed's ARIKAYCE business still growing?
Yes. Worldwide ARIKAYCE revenue was $92.8 million in the first quarter of 2025, up 22.9% from $75.5 million in the prior-year quarter, with growth in the U.S., Japan, and Europe. The company reiterated full-year 2025 global ARIKAYCE revenue guidance of $405 million to $425 million.
What is the key regulatory catalyst for investors?
The FDA accepted the New Drug Application for brensocatib in patients with bronchiectasis with Priority Review, and the PDUFA target action date is August 12, 2025. If approved, Insmed expects to launch brensocatib immediately in the U.S. Regulatory submissions have also been accepted in the EU and UK.
Why did operating expenses increase and how large is the net loss?
Research and development expenses rose to $152.6 million from $121.1 million and SG&A rose to $147.5 million from $93.1 million. The filing attributes these increases mainly to higher compensation and stock-based compensation from increased headcount, as well as manufacturing expenses and launch preparation for brensocatib. The net loss was $256.6 million, or $1.42 per share, compared with $157.1 million, or $1.06 per share, a year earlier.
What is the company's cash position and what is it doing with its convertible debt?
Insmed reported approximately $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2025. It issued a notice of redemption for all $569.5 million of its remaining 0.75% Convertible Senior Notes due 2028, with a redemption date of June 6, 2025. The company says this is expected to lower ongoing interest expense and reduce outstanding debt.
What upcoming clinical data readouts should investors watch?
Topline data from the Phase 2b study of TPIP in pulmonary arterial hypertension are expected in June 2025. Topline results from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps are expected by the end of 2025, and topline results from the Phase 3 ENCORE study of ARIKAYCE are anticipated in the first half of 2026.
04—Continue